Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, AVITA Medical Inc (NASDAQ: RCEL) closed at $8.94 down -36.42% from its previous closing price of $14.06. In other words, the price has decreased by -$36.42 from its previous closing price. On the day, 1.37 million shares were traded. RCEL stock price reached its highest trading level at $10.32 during the session, while it also had its lowest trading level at $8.51.
Ratios:
For a deeper understanding of AVITA Medical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.37 and its Current Ratio is at 3.73. In the meantime, Its Debt-to-Equity ratio is 3.73 whereas as Long-Term Debt/Eq ratio is at 3.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, D. Boral Capital on December 24, 2024, initiated with a Buy rating and assigned the stock a target price of $25.
On June 27, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $23.Cantor Fitzgerald initiated its Overweight rating on June 27, 2023, with a $23 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 05 ’24 when O’Toole David D bought 975 shares for $12.46 per share. The transaction valued at 12,152 led to the insider holds 23,734 shares of the business.
O’Toole David D bought 1,000 shares of RCEL for $8,900 on May 30 ’24. The CFO now owns 19,734 shares after completing the transaction at $8.90 per share. On Feb 28 ’24, another insider, O’Toole David D, who serves as the CFO of the company, bought 1,250 shares for $17.39 each. As a result, the insider paid 21,738 and bolstered with 18,734 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCEL now has a Market Capitalization of 234385328 and an Enterprise Value of 235606608. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.70 while its Price-to-Book (P/B) ratio in mrq is 19.17. Its current Enterprise Value per Revenue stands at 3.924 whereas that against EBITDA is -4.068.
Stock Price History:
Over the past 52 weeks, RCEL has reached a high of $18.93, while it has fallen to a 52-week low of $7.51. The 50-Day Moving Average of the stock is -27.79%, while the 200-Day Moving Average is calculated to be -14.13%.
Shares Statistics:
For the past three months, RCEL has traded an average of 105.39K shares per day and 157280 over the past ten days. A total of 26.22M shares are outstanding, with a floating share count of 24.63M. Insiders hold about 0.85% of the company’s shares, while institutions hold 24.78% stake in the company. Shares short for RCEL as of 1734048000 were 1156538 with a Short Ratio of 10.97, compared to 1731628800 on 1024101. Therefore, it implies a Short% of Shares Outstanding of 1156538 and a Short% of Float of 4.4299997.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of AVITA Medical Inc (RCEL) in the stock market.The consensus estimate for the next quarter is -$0.51, with high estimates of $0.4 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$2.23 and -$4.1 for the fiscal current year, implying an average EPS of -$3.44. EPS for the following year is -$1.05, with 8.0 analysts recommending between $1.41 and -$2.72.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $34.3M this quarter.It ranges from a high estimate of $38.28M to a low estimate of $29.47M. As of the current estimate, AVITA Medical Inc’s year-ago sales were $21.7MFor the next quarter, 7 analysts are estimating revenue of $34.31M. There is a high estimate of $40.82M for the next quarter, whereas the lowest estimate is $30.66M.
A total of 7 analysts have provided revenue estimates for RCEL’s current fiscal year. The highest revenue estimate was $110.44M, while the lowest revenue estimate was $102.91M, resulting in an average revenue estimate of $104.63M. In the same quarter a year ago, actual revenue was $76.65MBased on 11 analysts’ estimates, the company’s revenue will be $162.51M in the next fiscal year. The high estimate is $177.19M and the low estimate is $154.18M.
